Shares of TRex Bio are slated to make their trading debut Friday after the clinical-stage biotechnology company's initial public offering was priced at the low end of expectations, raising about $116.7 million.
The South San Francisco, Calif., company late Thursday said it is selling more than 8.33 million shares at $14 each, compared with an expected price range of $14 to $16.
TRex shares are due to begin trading later Friday on the Nasdaq Global Select Market under the symbol TRXB.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.